JP2020502248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502248A5 JP2020502248A5 JP2019534685A JP2019534685A JP2020502248A5 JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5 JP 2019534685 A JP2019534685 A JP 2019534685A JP 2019534685 A JP2019534685 A JP 2019534685A JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- treating
- compound
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000031464 Cavernous Central Nervous System Hemangioma Diseases 0.000 claims 2
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022105969A JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437181P | 2016-12-21 | 2016-12-21 | |
| US62/437,181 | 2016-12-21 | ||
| PCT/US2017/031836 WO2018118109A1 (en) | 2016-12-21 | 2017-05-09 | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105969A Division JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502248A JP2020502248A (ja) | 2020-01-23 |
| JP2020502248A5 true JP2020502248A5 (enExample) | 2020-06-18 |
| JP7117306B2 JP7117306B2 (ja) | 2022-08-12 |
Family
ID=62627011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534685A Active JP7117306B2 (ja) | 2016-12-21 | 2017-05-09 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
| JP2022105969A Active JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105969A Active JP7461414B2 (ja) | 2016-12-21 | 2022-06-30 | Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4509138A3 (enExample) |
| JP (2) | JP7117306B2 (enExample) |
| DK (1) | DK3558314T3 (enExample) |
| ES (1) | ES3002432T3 (enExample) |
| FI (1) | FI3558314T3 (enExample) |
| PL (1) | PL3558314T3 (enExample) |
| PT (1) | PT3558314T (enExample) |
| WO (1) | WO2018118109A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
| US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
| ES3002432T3 (en) * | 2016-12-21 | 2025-03-06 | Bioaxone Biosciences Inc | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
| WO2019014322A1 (en) | 2017-07-11 | 2019-01-17 | BioAxone BioSciences, Inc. | KINASE INHIBITORS FOR THE TREATMENT OF DISEASES |
| SI3877364T1 (sl) * | 2018-11-06 | 2025-02-28 | Cervello Therapeutics, Llc | Inhibitorji rock kinaze |
| WO2021085645A1 (ja) | 2019-11-01 | 2021-05-06 | キリンホールディングス株式会社 | 多成分試料における物質の構造決定方法 |
| JP7213839B2 (ja) * | 2019-11-21 | 2023-01-27 | キリンホールディングス株式会社 | 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法 |
| EP4063839A4 (en) * | 2019-11-21 | 2023-11-22 | Kirin Holdings Kabushiki Kaisha | METHOD FOR PREPARING A CRYSTAL STRUCTURAL ANALYSIS SAMPLE FOR STRUCTURAL ANALYSIS BY CRYSTAL SPONGE METHOD |
| CN115975940B (zh) * | 2021-10-15 | 2025-09-02 | 合肥中科普瑞昇生物医药科技有限公司 | 胃癌原代细胞的培养基和培养方法 |
| JPWO2023085369A1 (enExample) | 2021-11-11 | 2023-05-19 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014783A1 (en) * | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| JP2007523202A (ja) | 2004-02-24 | 2007-08-16 | ビオアクソン・テラプティーク・インコーポレーテッド | ４置換ピペリジン誘導体 |
| JP4652112B2 (ja) | 2005-04-26 | 2011-03-16 | 富士フイルム株式会社 | 投射型表示装置 |
| JP5313125B2 (ja) | 2007-02-28 | 2013-10-09 | 旭化成ファーマ株式会社 | スルホンアミド誘導体 |
| JP2011530518A (ja) | 2008-08-05 | 2011-12-22 | アボット・ラボラトリーズ | タンパク質キナーゼの阻害剤として有用な化合物 |
| US8957093B2 (en) | 2011-06-06 | 2015-02-17 | The Scripps Research Institute | N-biphenylmethylindole modulators of PPARG |
| JP6397831B2 (ja) * | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤の製造方法及びその中間体 |
| ES2774923T3 (es) * | 2014-04-28 | 2020-07-23 | China Resources Pharmaceutical Holdings Company Ltd | Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| US9687483B2 (en) | 2015-01-26 | 2017-06-27 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors |
| ES3002432T3 (en) * | 2016-12-21 | 2025-03-06 | Bioaxone Biosciences Inc | Rho kinase inhibitor ba-1049 (r) and active metabolites thereof |
-
2017
- 2017-05-09 ES ES17882341T patent/ES3002432T3/es active Active
- 2017-05-09 WO PCT/US2017/031836 patent/WO2018118109A1/en not_active Ceased
- 2017-05-09 DK DK17882341.5T patent/DK3558314T3/da active
- 2017-05-09 EP EP24208222.0A patent/EP4509138A3/en active Pending
- 2017-05-09 PL PL17882341.5T patent/PL3558314T3/pl unknown
- 2017-05-09 JP JP2019534685A patent/JP7117306B2/ja active Active
- 2017-05-09 FI FIEP17882341.5T patent/FI3558314T3/fi active
- 2017-05-09 EP EP17882341.5A patent/EP3558314B1/en active Active
- 2017-05-09 PT PT178823415T patent/PT3558314T/pt unknown
-
2022
- 2022-06-30 JP JP2022105969A patent/JP7461414B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502248A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| EP4321513A3 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| FI3558314T3 (fi) | Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita | |
| JP2018024670A5 (enExample) | ||
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| JP2015513557A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| WO2015171610A3 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| WO2017090039A3 (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| EP3412668A3 (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| JP2017517565A5 (enExample) | ||
| MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| WO2018071741A8 (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| JP2016540015A5 (enExample) | ||
| WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate | |
| MX2020012336A (es) | Formulacion farmaceutica. | |
| TN2015000356A1 (en) | Bicyclic compounds | |
| EP3419981A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| LT3124048T (lt) | Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui | |
| MX2017005586A (es) | Piperidinilpirazolopirimidinonas y utilización de las mismas. |